Julia Maria Adler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Julia Maria Adler has a total of 229 co-authors. Here are the top co-authors by number of shared publications:
- Jakob Trimpert
Institut für Virologie, Freie Universität Berlin
18 shared publications - Achim D. Gruber
Institute of Veterinary Pathology, Freie Universität Berlin, Berlin, Germany
7 shared publications - Chuanxiong Nie
Institut für Chemie und Biochemie Freie Universität Berlin Takustraße 3 14195 Berlin Deutschland
7 shared publications - Emanuel Wyler
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology, Berlin, Germany
7 shared publications - Rainer Haag
Institute of Chemistry and Biochemistry Freie Universität Berlin Berlin Germany
7 shared publications Azza Abdelgawad
Institut für Virologie, Freie Universität Berlin, Berlin, Germany
6 shared publications
Latest Publications
- Open Access
- 29 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 6951
A single mutation may contribute to accelerated evolution of SARS-CoV-2 toward Omicron
How SARS-CoV-2 Omicron evolved remains obscure. T492I, an Omicron-specific mutation encountered in SARS-CoV-2 nonstructural protein 4 (NSP4), enhances viral replication and alters nonstructural protein cleavage, inferring potentials to drive evolution. Through evolve-and-resequence experiments of SARS-CoV-2 wild-type (hCoV-19/USA/WA-CDC-02982585-001/2020, A) and Delta strains (B.1.617) with or without T492I, this study demonstrates that the NSP4 mutation T492I confers accelerated phenotypic adaption and a predisposition to the emergence of SARS-CoV-2 Omicron-like variants. The T492I-driven evolution results in accelerated enhancement in viral replication, infectivity, immune evasion capacity, receptor-binding affinity and potential for cross-species transmission. Aside from elevated mutation rates and impact on deaminases, positive epistasis between T492I and adaptive mutations could potentially mechanistically facilitate the shifts in mutation spectra and indirectly determines the Omicron-predisposing evolution. These suggest a potentially important role of the driver mutation T492I in the evolution of SARS-CoV-2 Omicron variants. Our findings highlight the existence and importance of mutation-driven predisposition in viral evolution.
- 29 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 6951
Open AccessA single mutation may contribute to accelerated evolution of SARS-CoV-2 toward Omicron
How SARS-CoV-2 Omicron evolved remains obscure. T492I, an Omicron-specific mutation encountered in SARS-CoV-2 nonstructural protein 4 (NSP4), enhances viral replication and alters nonstructural protein cleavage, inferring potentials to drive evolution. Through evolve-and-resequence experiments of SARS-CoV-2 wild-type (hCoV-19/USA/WA-CDC-02982585-001/2020, A) and Delta strains (B.1.617) with or without T492I, this study demonstrates that the NSP4 mutation T492I confers accelerated phenotypic adaption and a predisposition to the emergence of SARS-CoV-2 Omicron-like variants. The T492I-driven evolution results in accelerated enhancement in viral replication, infectivity, immune evasion capacity, receptor-binding affinity and potential for cross-species transmission. Aside from elevated mutation rates and impact on deaminases, positive epistasis between T492I and adaptive mutations could potentially mechanistically facilitate the shifts in mutation spectra and indirectly determines the Omicron-predisposing evolution. These suggest a potentially important role of the driver mutation T492I in the evolution of SARS-CoV-2 Omicron variants. Our findings highlight the existence and importance of mutation-driven predisposition in viral evolution.
- Open Access
- 25 November 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (49) , 67504-67513
Sulfated Cellulose Nanofiber Hydrogel with Mucus-Like Activities for Virus Inhibition
Mucus is the first defense barrier against viruses in the human immune system. Inspired by the mucus structure, we designed a highly sulfated hydrogel to bind viruses and prevent infection of the underlying cells. The hydrogel was formed by gelation of sulfated cellulose nanofiber (SCNF) with Ca2+. SCNF exhibited a mucin-like nanofiber structure with high numbers of sulfated groups. Based on the electrostatic interactions with a virus, SCNF could efficiently inhibit herpes simplex virus-1 (HSV-1) infection with a half-maximal inhibitory concentration (IC50) of 0.43 μg/mL, which is comparable to that of heparin (IC50 = 0.30 μg/mL). Benefiting from the multiporous structure and sulfate groups, the Ca2+-SCNF hydrogel could efficiently trap HSV-1 and inhibit the virus from attacking the underlying cells in a transwell model. Furthermore, SCNF also inhibited SARS-CoV-2 infection in a similar experimental setting. By integrating the advantages of high and broad-spectrum virus inhibitory activity as well as low toxicity, it is believed that the Ca2+-SCNF hydrogel can promote the development of highly biocompatible and efficient antiviral material with "binding and inhibition" capability and other diverse strategies.
- 25 November 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (49) , 67504-67513
Open AccessSulfated Cellulose Nanofiber Hydrogel with Mucus-Like Activities for Virus Inhibition
Mucus is the first defense barrier against viruses in the human immune system. Inspired by the mucus structure, we designed a highly sulfated hydrogel to bind viruses and prevent infection of the underlying cells. The hydrogel was formed by gelation of sulfated cellulose nanofiber (SCNF) with Ca2+. SCNF exhibited a mucin-like nanofiber structure with high numbers of sulfated groups. Based on the electrostatic interactions with a virus, SCNF could efficiently inhibit herpes simplex virus-1 (HSV-1) infection with a half-maximal inhibitory concentration (IC50) of 0.43 μg/mL, which is comparable to that of heparin (IC50 = 0.30 μg/mL). Benefiting from the multiporous structure and sulfate groups, the Ca2+-SCNF hydrogel could efficiently trap HSV-1 and inhibit the virus from attacking the underlying cells in a transwell model. Furthermore, SCNF also inhibited SARS-CoV-2 infection in a similar experimental setting. By integrating the advantages of high and broad-spectrum virus inhibitory activity as well as low toxicity, it is believed that the Ca2+-SCNF hydrogel can promote the development of highly biocompatible and efficient antiviral material with "binding and inhibition" capability and other diverse strategies.
- Open Access
- 30 July 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (32)
Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants
Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) has developed substantial antigenic variability. As the majority of the population now has pre-existing immunity due to infection or vaccination, the use of experimentally generated animal immune sera can be valuable for measuring antigenic differences between virus variants. Here, we immunized Syrian hamsters by two successive infections with one of nine SARS-CoV-2 variants. Their sera were titrated against 16 SARS-CoV-2 variants, and the resulting titers were visualized using antigenic cartography. The antigenic map shows a condensed cluster containing all pre-Omicron variants (D614G, Alpha, Delta, Beta, Mu, and an engineered B.1+E484K variant) and considerably more diversity among a selected panel of Omicron subvariants (BA.1, BA.2, BA.4/BA.5, the BA.5 descendants BF.7 and BQ.1.18, the BA.2.75 descendant BN.1.3.1, the BA.2-derived recombinants XBB.2 and EG.5.1, and the BA.2.86 descendant JN.1). Some Omicron subvariants were as antigenically distinct from each other as the wildtype is from the Omicron BA.1 variant. Compared to titers measured in human sera, titers in hamster sera are of higher magnitude, show less fold change, and result in a more compact antigenic map topology. The results highlight the potential of sera from hamsters for the continued antigenic characterization of SARS-CoV-2.
- 30 July 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (32)
Open AccessAntigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants
Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) has developed substantial antigenic variability. As the majority of the population now has pre-existing immunity due to infection or vaccination, the use of experimentally generated animal immune sera can be valuable for measuring antigenic differences between virus variants. Here, we immunized Syrian hamsters by two successive infections with one of nine SARS-CoV-2 variants. Their sera were titrated against 16 SARS-CoV-2 variants, and the resulting titers were visualized using antigenic cartography. The antigenic map shows a condensed cluster containing all pre-Omicron variants (D614G, Alpha, Delta, Beta, Mu, and an engineered B.1+E484K variant) and considerably more diversity among a selected panel of Omicron subvariants (BA.1, BA.2, BA.4/BA.5, the BA.5 descendants BF.7 and BQ.1.18, the BA.2.75 descendant BN.1.3.1, the BA.2-derived recombinants XBB.2 and EG.5.1, and the BA.2.86 descendant JN.1). Some Omicron subvariants were as antigenically distinct from each other as the wildtype is from the Omicron BA.1 variant. Compared to titers measured in human sera, titers in hamster sera are of higher magnitude, show less fold change, and result in a more compact antigenic map topology. The results highlight the potential of sera from hamsters for the continued antigenic characterization of SARS-CoV-2.
- Open Access
- 10 June 2024
- Published by Wiley in Advanced Materials
- Vol. 36 (32) , e2401745
Mucus‐Inspired Self‐Healing Hydrogels: A Protective Barrier for Cells against Viral Infection
Mucus is a dynamic biological hydrogel, composed primarily of the glycoprotein mucin, exhibits unique biophysical properties and forms a barrier protecting cells against a broad‐spectrum of viruses. Here, this work develops a polyglycerol sulfate‐based dendronized mucin‐inspired copolymer (MICP‐1) with ≈10% repeating units of activated disulfide as cross‐linking sites. Cryo‐electron microscopy (Cryo‐EM) analysis of MICP‐1 reveals an elongated single‐chain fiber morphology. MICP‐1 shows potential inhibitory activity against many viruses such as herpes simplex virus 1 (HSV‐1) and SARS‐CoV‐2 (including variants such as Delta and Omicron). MICP‐1 produces hydrogels with viscoelastic properties similar to healthy human sputum and with tuneable microstructures using linear and branched polyethylene glycol‐thiol (PEG‐thiol) as cross‐linkers. Single particle tracking microrheology, electron paramagnetic resonance (EPR) and cryo‐scanning electron microscopy (Cryo‐SEM) are used to characterize the network structures. The synthesized hydrogels exhibit self‐healing properties, along with viscoelastic properties that are tuneable through reduction. A transwell assay is used to investigate the hydrogel's protective properties against viral infection against HSV‐1. Live‐cell microscopy confirms that these hydrogels can protect underlying cells from infection by trapping the virus, due to both network morphology and anionic multivalent effects. Overall, this novel mucin‐inspired copolymer generates mucus‐mimetic hydrogels on a multi‐gram scale. These hydrogels can be used as models for disulfide‐rich airway mucus research, and as biomaterials.
- 10 June 2024
- Published by Wiley in Advanced Materials
- Vol. 36 (32) , e2401745
Open AccessMucus‐Inspired Self‐Healing Hydrogels: A Protective Barrier for Cells against Viral Infection
Mucus is a dynamic biological hydrogel, composed primarily of the glycoprotein mucin, exhibits unique biophysical properties and forms a barrier protecting cells against a broad‐spectrum of viruses. Here, this work develops a polyglycerol sulfate‐based dendronized mucin‐inspired copolymer (MICP‐1) with ≈10% repeating units of activated disulfide as cross‐linking sites. Cryo‐electron microscopy (Cryo‐EM) analysis of MICP‐1 reveals an elongated single‐chain fiber morphology. MICP‐1 shows potential inhibitory activity against many viruses such as herpes simplex virus 1 (HSV‐1) and SARS‐CoV‐2 (including variants such as Delta and Omicron). MICP‐1 produces hydrogels with viscoelastic properties similar to healthy human sputum and with tuneable microstructures using linear and branched polyethylene glycol‐thiol (PEG‐thiol) as cross‐linkers. Single particle tracking microrheology, electron paramagnetic resonance (EPR) and cryo‐scanning electron microscopy (Cryo‐SEM) are used to characterize the network structures. The synthesized hydrogels exhibit self‐healing properties, along with viscoelastic properties that are tuneable through reduction. A transwell assay is used to investigate the hydrogel's protective properties against viral infection against HSV‐1. Live‐cell microscopy confirms that these hydrogels can protect underlying cells from infection by trapping the virus, due to both network morphology and anionic multivalent effects. Overall, this novel mucin‐inspired copolymer generates mucus‐mimetic hydrogels on a multi‐gram scale. These hydrogels can be used as models for disulfide‐rich airway mucus research, and as biomaterials.
- Open Access
- 13 March 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Mucus-Inspired Self-Healing Hydrogels: A Protective Barrier for Cells against Viral Infection
Mucus is a dynamic biological hydrogel, composed primarily of the glycoprotein mucin, exhibits unique biophysical properties and forms a barrier protecting cells against a broad spectrum of viruses. Here we developed a polyglycerol sulfate-based dendronized mucin-inspired copolymer (MICP-1) with ~10 % repeating units of activated disulfide as cross-linking sites. Cryo-EM analysis of MICP-1 reveals an elongated single-chain fiber morphology. MICP-1 shows potential inhibitory activity against many viruses such as HSV-1 and SARS-CoV-2 (including variants such as Delta and Omicron). MICP-1 produces hydrogels with viscoelastic properties similar to healthy human sputum and with tuneable microstructures using linear and branched PEG-thiol as cross-linkers. Single particle tracking microrheology, EPR and Cryo-SEM were used to characterize the network structures. The synthesized hydrogels exhibit self-healing properties, along with viscoelastic properties that are tuneable through reduction. a transwell assay was used to investigate the hydrogel’s protective properties against viral infection against HSV-1. Live-cell microscopy confirmed that these hydrogels can protect underlying cells from infection by trapping the virus, due to both network morphology and anionic multivalent effects. Overall, our novel mucin-inspired copolymer generates mucus-mimetic hydrogels on a multi-gram scale. These hydrogels can be used as a models for disulfide-rich airway mucus research, and as biomaterials.
- 13 March 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessMucus-Inspired Self-Healing Hydrogels: A Protective Barrier for Cells against Viral Infection
Mucus is a dynamic biological hydrogel, composed primarily of the glycoprotein mucin, exhibits unique biophysical properties and forms a barrier protecting cells against a broad spectrum of viruses. Here we developed a polyglycerol sulfate-based dendronized mucin-inspired copolymer (MICP-1) with ~10 % repeating units of activated disulfide as cross-linking sites. Cryo-EM analysis of MICP-1 reveals an elongated single-chain fiber morphology. MICP-1 shows potential inhibitory activity against many viruses such as HSV-1 and SARS-CoV-2 (including variants such as Delta and Omicron). MICP-1 produces hydrogels with viscoelastic properties similar to healthy human sputum and with tuneable microstructures using linear and branched PEG-thiol as cross-linkers. Single particle tracking microrheology, EPR and Cryo-SEM were used to characterize the network structures. The synthesized hydrogels exhibit self-healing properties, along with viscoelastic properties that are tuneable through reduction. a transwell assay was used to investigate the hydrogel’s protective properties against viral infection against HSV-1. Live-cell microscopy confirmed that these hydrogels can protect underlying cells from infection by trapping the virus, due to both network morphology and anionic multivalent effects. Overall, our novel mucin-inspired copolymer generates mucus-mimetic hydrogels on a multi-gram scale. These hydrogels can be used as a models for disulfide-rich airway mucus research, and as biomaterials.
- Open Access
Improving the Antigenicity of SARS-CoV-2 Vaccine Genes by Merging Mutations from Different Variants of Concern
During the COVID-19 pandemic, the early emergence of viral variants repeatedly undermined the effects of vaccination. Our aim here is to explore strategies for improving spike vaccine gene antigenicity by merging mutations from different variants of concern (VOCs) in a single vaccine gene. To this end, newly developed recombinant vaccine genes were designed, cloned into adenoviral vectors, and applied to C57BL/6 mice; then, serum-neutralizing antibodies against the wildtype SARS-CoV-2 strains were determined in neutralization assays. The merger of mutations from different variants of concern (alpha, beta, gamma, and delta) in a single recombinant spike-based vaccine gene provided a substantial improvement in neutralizing immunity to all variants of concern, including the omicron strains. To date, only unmodified spike genes of the original SARS-CoV-2 Wuhan strain (B.1) or dominant variants (BA.1, BA.5, and XBB.1.5) have been used as vaccine genes. The employment of unmodified vaccine genes is afflicted by limited cross-protection among variant strains. In contrast, recombinant vaccine genes that combine mutations from different strains in a single gene hold the potential to broaden and improve immune protection and might help to reduce the need for frequent vaccine adaptations in the future.
Open AccessImproving the Antigenicity of SARS-CoV-2 Vaccine Genes by Merging Mutations from Different Variants of Concern
During the COVID-19 pandemic, the early emergence of viral variants repeatedly undermined the effects of vaccination. Our aim here is to explore strategies for improving spike vaccine gene antigenicity by merging mutations from different variants of concern (VOCs) in a single vaccine gene. To this end, newly developed recombinant vaccine genes were designed, cloned into adenoviral vectors, and applied to C57BL/6 mice; then, serum-neutralizing antibodies against the wildtype SARS-CoV-2 strains were determined in neutralization assays. The merger of mutations from different variants of concern (alpha, beta, gamma, and delta) in a single recombinant spike-based vaccine gene provided a substantial improvement in neutralizing immunity to all variants of concern, including the omicron strains. To date, only unmodified spike genes of the original SARS-CoV-2 Wuhan strain (B.1) or dominant variants (BA.1, BA.5, and XBB.1.5) have been used as vaccine genes. The employment of unmodified vaccine genes is afflicted by limited cross-protection among variant strains. In contrast, recombinant vaccine genes that combine mutations from different strains in a single gene hold the potential to broaden and improve immune protection and might help to reduce the need for frequent vaccine adaptations in the future.
- Open Access
- 2 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission
The development of effective SARS-CoV-2 vaccines has been essential to control COVID-19, but significant challenges remain. One problem is intramuscular administration, which does not induce robust mucosal immune responses in the upper airways—the primary site of infection and virus shedding. Here we compare the efficacy of a mucosal, replication-competent yet fully attenuated virus vaccine, sCPD9-ΔFCS, and the monovalent mRNA vaccine BNT162b2 in preventing transmission of SARS-CoV-2 variants B.1 and Omicron BA.5 in two scenarios. Firstly, we assessed the protective efficacy of the vaccines by exposing vaccinated male Syrian hamsters to infected counterparts. Secondly, we evaluated transmission of the challenge virus from vaccinated and subsequently challenged male hamsters to naïve contacts. Our findings demonstrate that the live-attenuated vaccine (LAV) sCPD9-ΔFCS significantly outperformed the mRNA vaccine in preventing virus transmission in both scenarios. Our results provide evidence for the advantages of locally administered LAVs over intramuscularly administered mRNA vaccines in preventing infection and reducing virus transmission.
- 2 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Open AccessAn intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission
The development of effective SARS-CoV-2 vaccines has been essential to control COVID-19, but significant challenges remain. One problem is intramuscular administration, which does not induce robust mucosal immune responses in the upper airways—the primary site of infection and virus shedding. Here we compare the efficacy of a mucosal, replication-competent yet fully attenuated virus vaccine, sCPD9-ΔFCS, and the monovalent mRNA vaccine BNT162b2 in preventing transmission of SARS-CoV-2 variants B.1 and Omicron BA.5 in two scenarios. Firstly, we assessed the protective efficacy of the vaccines by exposing vaccinated male Syrian hamsters to infected counterparts. Secondly, we evaluated transmission of the challenge virus from vaccinated and subsequently challenged male hamsters to naïve contacts. Our findings demonstrate that the live-attenuated vaccine (LAV) sCPD9-ΔFCS significantly outperformed the mRNA vaccine in preventing virus transmission in both scenarios. Our results provide evidence for the advantages of locally administered LAVs over intramuscularly administered mRNA vaccines in preventing infection and reducing virus transmission.
- Open Access
Neural Network-Assisted Humanization of COVID-19 Hamster scRNAseq Data Reveals Matching Severity States in Human Disease
Translating findings from animal models to human disease is essential for dissecting disease mechanisms, developing and testing precise therapeutic strategies. The coronavirus disease 2019 (COVID-19) pandemic has highlighted this need, particularly for models showing disease severity-dependent immune responses. Single-cell transcriptomics (scRNAseq) is well poised to reveal similarities and differences between species at the molecular and cellular level with unprecedented resolution. However, computational methods enabling detailed matching are still scarce. Here, we provide a structured scRNAseq-based approach that we applied to scRNAseq from blood leukocytes originating from humans and hamsters affected with moderate or severe COVID-19. Integration of COVID-19 patient data with two hamster models that develop moderate (Syrian hamster, Mesocricetus auratus ) or severe (Roborovski hamster, Phodopus roborovskii ) disease revealed that most cellular states are shared across species. A neural network-based analysis using variational autoencoders quantified the overall transcriptomic similarity across species and severity levels, showing highest similarity between neutrophils of Roborovski hamsters and severe COVID-19 patients, while Syrian hamsters better matched patients with moderate disease, particularly in classical monocytes. We further used transcriptome-wide differential expression analysis to identify which disease stages and cell types display strongest transcriptional changes. Consistently, hamster’s response to COVID-19 was most similar to humans in monocytes and neutrophils. Disease-linked pathways found in all species specifically related to interferon response or inhibition of viral replication. Analysis of candidate genes and signatures supported the results. Our structured neural network-supported workflow could be applied to other diseases, allowing better identification of suitable animal models with similar pathomechanisms across species. Key Points: Neural networks can successfully match disease states between animal models and humans using single-cell data as shown for COVID-19 Moderately diseased patients best matched Syrian hamster cells; severely diseased patients best matched Roborovski hamster neutrophils
Open AccessNeural Network-Assisted Humanization of COVID-19 Hamster scRNAseq Data Reveals Matching Severity States in Human Disease
Translating findings from animal models to human disease is essential for dissecting disease mechanisms, developing and testing precise therapeutic strategies. The coronavirus disease 2019 (COVID-19) pandemic has highlighted this need, particularly for models showing disease severity-dependent immune responses. Single-cell transcriptomics (scRNAseq) is well poised to reveal similarities and differences between species at the molecular and cellular level with unprecedented resolution. However, computational methods enabling detailed matching are still scarce. Here, we provide a structured scRNAseq-based approach that we applied to scRNAseq from blood leukocytes originating from humans and hamsters affected with moderate or severe COVID-19. Integration of COVID-19 patient data with two hamster models that develop moderate (Syrian hamster, Mesocricetus auratus ) or severe (Roborovski hamster, Phodopus roborovskii ) disease revealed that most cellular states are shared across species. A neural network-based analysis using variational autoencoders quantified the overall transcriptomic similarity across species and severity levels, showing highest similarity between neutrophils of Roborovski hamsters and severe COVID-19 patients, while Syrian hamsters better matched patients with moderate disease, particularly in classical monocytes. We further used transcriptome-wide differential expression analysis to identify which disease stages and cell types display strongest transcriptional changes. Consistently, hamster’s response to COVID-19 was most similar to humans in monocytes and neutrophils. Disease-linked pathways found in all species specifically related to interferon response or inhibition of viral replication. Analysis of candidate genes and signatures supported the results. Our structured neural network-supported workflow could be applied to other diseases, allowing better identification of suitable animal models with similar pathomechanisms across species. Key Points: Neural networks can successfully match disease states between animal models and humans using single-cell data as shown for COVID-19 Moderately diseased patients best matched Syrian hamster cells; severely diseased patients best matched Roborovski hamster neutrophils
- Open Access
Single-cell-resolved interspecies comparison identifies a shared inflammatory axis and a dominant neutrophil-endothelial program in severe COVID-19
Key issues for research of COVID-19 pathogenesis are the lack of biopsies from patients and of samples at the onset of infection. To overcome these hurdles, hamsters were shown to be useful models for studying this disease. Here, we further leveraged the model to molecularly survey the disease progression from time-resolved single-cell RNA-sequencing data collected from healthy and SARS-CoV-2-infected Syrian and Roborovski hamster lungs. We compared our data to human COVID-19 studies, including BALF, nasal swab, and post-mortem lung tissue, and identified a shared axis of inflammation dominated by macrophages, neutrophils, and endothelial cells, which we show to be transient in Syrian and terminal in Roborovski hamsters. Our data suggest that, following SARS-CoV-2 infection, commitment to a type 1 or type 3-biased immunity determines moderate versus severe COVID-19 outcomes, respectively. One-Sentence Summary: Activation of different immunological programs upon SARS-CoV-2 infection determines COVID-19 severity.
Open AccessSingle-cell-resolved interspecies comparison identifies a shared inflammatory axis and a dominant neutrophil-endothelial program in severe COVID-19
Key issues for research of COVID-19 pathogenesis are the lack of biopsies from patients and of samples at the onset of infection. To overcome these hurdles, hamsters were shown to be useful models for studying this disease. Here, we further leveraged the model to molecularly survey the disease progression from time-resolved single-cell RNA-sequencing data collected from healthy and SARS-CoV-2-infected Syrian and Roborovski hamster lungs. We compared our data to human COVID-19 studies, including BALF, nasal swab, and post-mortem lung tissue, and identified a shared axis of inflammation dominated by macrophages, neutrophils, and endothelial cells, which we show to be transient in Syrian and terminal in Roborovski hamsters. Our data suggest that, following SARS-CoV-2 infection, commitment to a type 1 or type 3-biased immunity determines moderate versus severe COVID-19 outcomes, respectively. One-Sentence Summary: Activation of different immunological programs upon SARS-CoV-2 infection determines COVID-19 severity.
- Open Access
- 14 June 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (29)
Mucin‐inspirierte Einzelstrang‐Polymerfasern (MIP) als wirksame SARS‐CoV‐2‐Inhibitoren
Mucine sind eine Schlüsselkomponente der defensiven Schleimbarriere. Es handelt sich um ausgedehnte Fasern mit sehr hohem Molekulargewicht, deren vielfältige biologische Funktionen stark von ihren spezifischen Strukturparametern abhängen. Hier stellen wir eine Mucin‐inspirierte Nanostruktur basierend auf dendronisierten Polysulfaten auf Methacrylatbasis (MIP‐1) mit hohem Molekulargewicht (MW=450 kDa) vor. Das Thiol‐End‐funktionalisierte Mucin‐inspiriertem Polymer (MIP) wurde durch RAFT‐Polymerisation im Multi‐Gramm‐Maßstab hergestellt. Die Kryo‐Elektronentomographie‐Analyse (Kryo‐ET) von MIP‐1 bestätigte eine Mucin‐artige, wurmartige einkettige Faserstruktur (Länge=144±59 nm) in wässriger Lösung. Diese biokompatible Faser zeigte eine vielversprechende Aktivität mit einer bemerkenswert niedrigen mittleren inhibitorischen Konzentration (IC50, mit IC50=10.0 nM) gegenüber SARS‐CoV‐2 und dessen Mutantenstamm. Darüber hinaus untersuchen wir die Auswirkungen der Faserlänge auf die Hemmung gegenüber SARS‐CoV‐2, indem wir andere funktionelle Polymere (MIPs) mit unterschiedlichen Faserlängen miteinander vergleichen.
- 14 June 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (29)
Open AccessMucin‐inspirierte Einzelstrang‐Polymerfasern (MIP) als wirksame SARS‐CoV‐2‐Inhibitoren
Mucine sind eine Schlüsselkomponente der defensiven Schleimbarriere. Es handelt sich um ausgedehnte Fasern mit sehr hohem Molekulargewicht, deren vielfältige biologische Funktionen stark von ihren spezifischen Strukturparametern abhängen. Hier stellen wir eine Mucin‐inspirierte Nanostruktur basierend auf dendronisierten Polysulfaten auf Methacrylatbasis (MIP‐1) mit hohem Molekulargewicht (MW=450 kDa) vor. Das Thiol‐End‐funktionalisierte Mucin‐inspiriertem Polymer (MIP) wurde durch RAFT‐Polymerisation im Multi‐Gramm‐Maßstab hergestellt. Die Kryo‐Elektronentomographie‐Analyse (Kryo‐ET) von MIP‐1 bestätigte eine Mucin‐artige, wurmartige einkettige Faserstruktur (Länge=144±59 nm) in wässriger Lösung. Diese biokompatible Faser zeigte eine vielversprechende Aktivität mit einer bemerkenswert niedrigen mittleren inhibitorischen Konzentration (IC50, mit IC50=10.0 nM) gegenüber SARS‐CoV‐2 und dessen Mutantenstamm. Darüber hinaus untersuchen wir die Auswirkungen der Faserlänge auf die Hemmung gegenüber SARS‐CoV‐2, indem wir andere funktionelle Polymere (MIPs) mit unterschiedlichen Faserlängen miteinander vergleichen.